Sugi Predict

Sugi Predict / Compounds / SCHEMBL1674757

SCHEMBL1674757

SCHEMBL1674757

NC(CCC(=O)O)C(=O)NC(CC(=O)O)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 1/20 0.54
▸ DPP8 Q6V1X1 1/20 0.54
▸ DPP9 Q86TI2 1/20 0.54
▸ GRM8 O00222 1/20 0.53
▸ GRM6 O15303 1/20 0.53
▸ GRIN2D O15399 1/20 0.53
▸ GRIN3B O60391 1/20 0.53
▸ GSR P00390 1/20 0.53
▸ CYP1A2 P05177 1/20 0.53
▸ GRIK1 P39086 1/20 0.53
▸ GRM5 P41594 1/20 0.53
▸ GRIA1 P42261 1/20 0.53
▸ GRIA2 P42262 1/20 0.53
▸ GRIA3 P42263 1/20 0.53
▸ SLC1A3 P43003 1/20 0.53
▸ SLC1A2 P43004 1/20 0.53
▸ SLC1A1 P43005 1/20 0.53
▸ GRIA4 P48058 1/20 0.53
▸ GRIN1 Q05586 1/20 0.53
▸ GRIN2A Q12879 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29517676 1.00 DPP4 (0.54) DPP4DPP8DPP9GRM8GRM6
SCHEMBL1674753 1.00 DPP4 (0.54) DPP4DPP8DPP9GRM8GRM6
SCHEMBL29379253 0.98 DPP4 (0.53) DPP4DPP8DPP9GRM8GRM6
SCHEMBL31287182 0.98 DPP4 (0.53) DPP4DPP8DPP9GRM8GRM6
SCHEMBL28482649 0.98 DPP4 (0.53) DPP4DPP8DPP9GRM8GRM6
SCHEMBL30099544 0.95 DPP4 (0.50) DPP4DPP8DPP9GRM8GRM6
SCHEMBL31453847 0.95 DPP4 (0.50) DPP4DPP8DPP9GRM8GRM6
SCHEMBL30099498 0.95 DPP4 (0.50) DPP4DPP8DPP9GRM8GRM6
SCHEMBL30099651 0.95 DPP4 (0.50) DPP4DPP8DPP9GRM8GRM6
SCHEMBL30099554 0.95 DPP4 (0.50) DPP4DPP8DPP9GRM8GRM6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112125821-A Aqueous solution containing N-long-chain acyl acidic amino acid and/or salt thereof, and method for producing same 味之素株式会社 2020-12-25 — — CN claimed
EP-2661266-A2 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES Elcelyx Therapeutics, Inc. (US) 2013-11-13 — — EP claimed
WO-2012094636-A2 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES ELCELYX THERAPEUTICS, INC. (US) 2012-07-12 — — WO claimed
US-20240108040-A1 HIGH INTENSITY SWEETENERS FIRMENICH INCORPORATED (US) 2024-04-04 — — US disclosed
CN-117504137-B Cardiac pacemaker fixing device and preparation method thereof 山东瑞安泰医疗技术有限公司 2024-03-12 — — CN disclosed
CN-117504137-A Cardiac pacemaker fixing device and preparation method thereof 山东瑞安泰医疗技术有限公司 2024-02-06 — — CN disclosed
US-11758933-B2 High intensity sweeteners FIRMENICH INCORPORATED (US) 2023-09-19 — — US disclosed
CN-116686968-A Layered coated porous microsphere type sodium-reducing salt-substituting salty flavoring and preparation method thereof 北京海德恒生科技发展有限公司 2023-09-05 — — CN disclosed
EP-3368542-B1 HIGH INTENSITY SWEETENERS FIRMENICH INCORPORATED (US) 2022-06-22 — — EP disclosed
US-11357246-B2 High intensity sweeteners FIRMENICH INCORPORATED (US) 2022-06-14 — — US disclosed
US-20210227863-A1 HIGH INTENSITY SWEETENERS SENOMYX, INC. 2021-07-29 — — US disclosed
US-20120177730-A1 Chemosensory Receptor Ligand-Based Therapies ELCELYX THERAPEUTICS, INC. (US) 2012-07-12 — — US disclosed
WO-2012054528-A2 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES ELCELYX THERAPEUTICS, INC. (US) 2012-04-26 — — WO disclosed
US-20110177545-A1 G-PROTEINS GIVAUDAN SA (CH) 2011-07-21 — — US disclosed
US-7919236-B2 G-proteins GIVAUDAN SA (CH) 2011-04-05 — — US disclosed
EP-1581555-B1 CHIMERIC ALPHA Q-GUSTDUCIN G-PROTEINS GIVAUDAN SA (CH) 2008-04-30 — — EP disclosed
US-20060275765-A1 G-proteins GIVAUDAN SA (CH) 2006-12-07 — — US disclosed
EP-1581555-A2 G-PROTEINS Givaudan SA (CH) 2005-10-05 — — EP disclosed
WO-2004055048-A2 CHIMERIC ALPHA Q-GUSTDUCIN G-PROTEINS GIVAUDAN SA (CH) 2004-07-01 — — WO disclosed
US-4975418-A Therapeutically active compositions of pseudo-peptide of glutamyl-aspartic acid CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIC (CNRS) (FR) 1990-12-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240108040-A1 HIGH INTENSITY SWEETENERS TAS2R40, TAS2R60, TAS1R1 DPP4 743/4885DPP8 1035/4885DPP9 924/4885
US-20120177730-A1 Chemosensory Receptor Ligand-Based Therapies TAS1R2, TAS2R1, GPR119 DPP4 360/4885DPP8 710/4885DPP9 547/4885
US-11357246-B2 High intensity sweeteners TAS2R40, TAS2R60, TAS1R1 DPP4 743/4885DPP8 1035/4885DPP9 924/4885
US-20210227863-A1 HIGH INTENSITY SWEETENERS TAS2R40, TAS2R60, TAS1R1 DPP4 743/4885DPP8 1035/4885DPP9 924/4885
US-11758933-B2 High intensity sweeteners TAS2R40, TAS2R60, TAS1R1 DPP4 743/4885DPP8 1035/4885DPP9 924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.